Next Phase Newsletter

A venture capital firm newly founded in 2023 and dually headquartered in the U.S. and Europe  is looking to invest from its new fund in life science startups typically in the Series A round. Typical check size is flexible but ranges from $250k-2M. The firm is looking to invest in companies from the U.S., Europe, Israel, and the Middle East. The firm’s co-founder is NIH trained and has done consulting with the FDA, bringing their expertise to investments and companies.

The firm is investing in life science sectors including: 50% in therapeutics, 20% in medical devices, 20% in diagnostics, and 10% in health-tech. The firm is open to all modalities and technologies. In terms of therapeutics, the firm prefers companies that are Pre-Clinical up to Phase II and will not look farther than that. The firm is indication-agnostic and is open to looking at orphan diseases.

The firm may take a board seat on a case-by-case basis but does not have specific management team requirements. The firm can participate as a lead investor or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

One of the leading fully integrated biopharmaceutical companies in China with multiple integrated R&D centers in US and China is actively seeking licensing/collaboration on development candidates with first-in-class or best-in-class potentials and commercial products with substantial market opportunities in China and worldwide.

The firm is actively looking for innovative drug candidates in all stages in the therapeutic areas of Oncology, CNS, Autoimmune and Infectious disease.

The firm is looking for companies with capacity and experience to implement R&D plans. The firm is interested in incubating companies from scratch.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund based in the US looks to make initial equity investments ranging anywhere from $750,000 and up, with most investments falling in the $2-3M million range for the life of the investment. The firm is actively seeking new investments in the US.

The firm is interested in healthcare software companies and tech-enabled healthcare services, with a deep interest in software platforms for clinical trials and pharma services. The firm is interested in B2B SaaS business models and those that have some initial customer traction. The firm is not interested in therapeutics, medical devices, or diagnostics.

The firm does not look to take controlling investments in companies. They take a board seat following investment. The firm is interested in privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm in Taipei, Taiwan invests in several sectors including biotechnology, semiconductors, commerce, materials, and software. The firm will invest in companies in Series A and B in Taiwan, Japan, and the U.S. Typical check size ranges from $1-3M USD for early-stage deals. The firm also has an angel fund for Seed stage companies with typical check sizes ranging from $100-3000k USD. Currently, 70% of the firm’s portfolio companies are in Taiwan or Taiwanese-related and 30% are in the U.S. or Japan. The firm has an extended network in the U.S., especially from the Silicon Valley and Boston as most of the founding partners are from Stanford University. If the firm is investing in a Taiwanese company, they tend to lead investments, but for overseas investments, the firm will mostly act as a co-investor.

The firm focuses on biomaterials, medical devices and digital health at in-development or clinical stages. The firm does not invest in pharma or drug development. In terms of medical devices, the firm likes to look at surgery-related devices and for digital health, the firm like to look at software for long-term care. Though, firm is open to all indications and can look at orphan diseases depending on the technology.

The firm focuses on companies that can finalize assets by maximum of 9 years due to the limited fund. The firm may take an observer seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A multi-family venture fund is an active investor in the medical device sector, and is interested in opportunities in the western United States. Initial investments are typically about $150,000 with the potential for follow-on investments totaling $1 million and may be structured as equity or as debt. The firm offers support and expertise to portfolio companies but does not seek a board seat.

The firm is interested in medical technology and lab equipment, including electro-mechanical medical devices, active implantable devices, and surgical instruments. The firm invests only in companies that have already developed a prototype of their product, filed a patent application and have animal data.

The firm seeks to invest in strong management teams with prior experience in the medical device industry. The firm prefers to make investments with the potential to exit within 3-4 years.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital investment firm based in the US that is supported by a family office who has invested in healthcare operating companies and real estate for over 30 years, seeks to invest in opportunities that align with their strategic interests. Investments in healthcare have included skilled nursing facilities, rehabilitation therapy, institutional pharmacy, hospice, mental health tech, healthcare tech, and home health. The firm looks to work with early stage companies where they can leverage their operating platform.  As a private investor, the firm has a very flexible horizon and mandate – investment size can greatly vary on a deal-by-deal basis. The firm has about 20 companies in their its portfolio, and invests all across the USA.

The firm has a robust portfolio that ranges from healthcare to technology to consumer products. While the firm has a broad interest in healthcare, the firm is most interested in technologies that can leverage the firm’s operating platform and resources. The firm’s portfolio companies include workforce transformation, nurse staffing, medical billing, and Fintech that is focused on the healthcare sector, medical billing, and more. The firm also has a strong interest in technologies dedicated to mental & behavioral health. The firm is opportunistic in terms of stage of development. The firm does not consider therapeutics opportunities.

The firm seeks to partner with smart, thoughtful founders with a true commitment in their ideas. The firm is a hands-on investor and seeks to have an active role in their portfolio companies. As mentioned above, the firm is able to leverage its resources to support pilots and enable companies to test new ideas. The firm can also support companies in enhancing their business models, implementing scale through partnerships, and share their own experiences in developing world-class brands.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm that is a division of a Japan-based manufacturer of various goods including pharmaceuticals, chemicals, etc. – one of the largest privately held companies in Japan – is actively looking for global partnering opportunities that complement the firm’s current research pipeline. Types of partnerships can include in-licensing, co-development, co-commercialization, and potentially more. Though the firm is capable of making investments and may expand upon their methods of partnering with early-stage companies, the firm does not currently have a dedicated venture capital fund.

The firm is primarily interested in therapeutics that complement the firm’s current research pipeline which includes assets in cardiovascular disease, metabolic disease, peripheral arterial disease, and pain management. The firm is interested in novel compounds that they can develop through proof of concept, and is generally stage agnostic. While the firm has historically focused on small molecules, the firm has a growing interest in antibodies and cell therapies. In addition, the firm is strongly interested in platform technologies.

The firm does not have specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.